...
首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >Tamoxifen promotes superoxide production in platelets by activation of PI3-Kinase and NADPH oxidase pathways
【24h】

Tamoxifen promotes superoxide production in platelets by activation of PI3-Kinase and NADPH oxidase pathways

机译:他莫昔芬通过激活PI3-激酶和NADPH氧化酶途径促进血小板中超氧化物的产生

获取原文
获取原文并翻译 | 示例

摘要

Background: Tamoxifen is a selective estrogen receptor antagonist that is widely used for treatment and prevention of breast cancer. However, tamoxifen use can lead to an increased incidence of thrombotic events. The reason for this adverse event remains unknown. Previous studies showed that tamoxifen and its active metabolite Z-4-hydroxytamoxifen rapidly increased intracellular free calcium ([Ca 2+] i) in human platelets by a non-genomic mechanism that involved the activation of phospholipase C. Platelets play a pivotal role in thrombosis and Ca 2+ elevation is a central event in platelet activation. Therefore the mechanism by which tamoxifen activated Ca 2+ entry into platelets was investigated. Methods: [Ca 2+] i was measured using the fluorescent indicator fura-2 and reactive oxygen species were measured using lucigenin in isolated human platelets. Results: Tamoxifen analogs E-4-hydroxytamoxifen, with weak activity at the nuclear estrogen receptor and Z-4-hydroxytamoxifen, with strong activity at nuclear estrogen receptor, were equally active at increasing [Ca 2+] i and synergizing with ADP and thrombin to increase [Ca 2+] i in platelets. This result suggests that the effects of tamoxifen and E- and Z-4-hydroxytamoxifen to increase [Ca 2+] i are not mediated by the classical genomic estrogen receptor. The effects of tamoxifen to increase [Ca 2+] i were strongly inhibited by apocynin and apocynin dimer. This suggests that tamoxifen activates NADPH oxidase which leads to superoxide generation and in turn caused an increase in [Ca 2+] i. Free radical scavengers TEMPO and TEMPOL also inhibited tamoxifen-induced [Ca 2+] i elevation. Inhibition of phosphoinositide-3-kinase (PI3-kinase), an upstream effector of NADPH oxidase with wortmannin and LY-294,002 also caused substantial inhibition of tamoxifen-induced elevation of [Ca 2+] i. Conclusion: Tamoxifen increases [Ca 2+] i in human platelets by a non-genomic mechanism. Tamoxifen activates phospholipase Cγ as well as PI3-kinase and NADPH oxidase pathway to generate superoxide which causes the release of Ca 2+ from the endoplasmic reticulum, and promotes Ca 2+ influx into the platelets.
机译:背景:他莫昔芬是一种选择性雌激素受体拮抗剂,被广泛用于治疗和预防乳腺癌。但是,他莫昔芬的使用会导致血栓形成事件的发生率增加。这种不良事件的原因仍然未知。先前的研究表明,他莫昔芬及其活性代谢物Z-4-羟基他莫昔芬通过涉及磷脂酶C活化的非基因机制迅速增加人血小板中的细胞内游离钙([Ca 2+] i)。血小板在其中起关键作用。血栓形成和Ca 2+升高是血小板激活的中心事件。因此,研究了他莫昔芬激活Ca 2+进入血小板的机制。方法:使用荧光指示剂fura-2测定[Ca 2+] i,并使用荧光素原测定分离的人血小板中的活性氧。结果:对核雌激素受体活性弱的三苯氧胺类似物E-4-羟基他莫昔芬和对核雌激素受体活性强的Z-4-羟基他莫昔芬对增加[Ca 2+] i以及与ADP和凝血酶的协同作用均相同。增加血小板中的[Ca 2+] i。该结果表明,他莫昔芬和E-和Z-4-羟基他莫昔芬增加[Ca 2+] i的作用不是由经典基因组雌激素受体介导的。阿朴西林和阿朴西宁二聚体强烈抑制了他莫昔芬增加[Ca 2+] i的作用。这表明他莫昔芬激活NADPH氧化酶,从而导致超氧化物的产生,进而引起[Ca 2+] i的增加。自由基清除剂TEMPO和TEMPOL也抑制他莫昔芬诱导的[Ca 2+] i升高。磷酸肌苷-3-激酶(PI3-激酶)是渥曼青霉素和LY-294,002对NADPH氧化酶的上游效应物的抑制作用,也引起三苯氧胺诱导的[Ca 2+] i升高。结论:他莫昔芬通过非基因组机制增加人血小板中的[Ca 2+] i。他莫昔芬激活磷脂酶Cγ以及PI3-激酶和NADPH氧化酶途径,产生超氧化物,引起内质网中Ca 2+的释放,并促进Ca 2+流入血小板。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号